肝癌早期诊断标志物的研究新进展

doi:10.20047/j.issn1673-7210.2023.01.08

Abstract
Figure/Table
References (34)
Related Citation (15)

Download: PDF (576 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Hepatocellular carcinoma is one of the malignant tumors with the highest morbidity and mortality in our country, which poses a serious burden to society. Liver ultrasound and tumor marker alphafetoprotein (AFP) are the most widely used tests in the world. However, ultrasound and AFP have limited accuracy in the detection of early liver cancer. At present, many studies are looking for reliable biomarkers for the diagnosis of early liver cancer. Such biomarkers will help in the diagnosis of early liver cancer and ensure early detection, diagnosis, and treatment. This review summarizes the role of protein markers, gene markers (non-coding RNA and DNA methylation) as biomarkers in the identification of early liver cancer, and discuss their potential significance as biomarkers in the diagnosis of early liver cancer.

Key words： Liver cancer Early diagnosis Protein biomarker Non-coding RNA DNA methylation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Wenliang XU Ximing

Cite this article:

CHEN Wenliang XU Ximing. New progress in the study of markers for the early diagnosis of liver cancer[J]. 中国医药导报, 2023, 20(1): 40-44.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.01.08 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I1/40

[1] Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Liu D，Song T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China [J]. Biosci Trends，2021，15（3）：142-147.
[3] Pi?觡ero F，Dirchwolf M，Pess?觝a MG. Biomarkers in Hepatocellular Carcinoma：Diagnosis，Prognosis and Treatment Response Assessment [J]. Cells，2020，9（6）：1370.
[4] Chang TS，Wu YC，Tung SY，et al. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis [J]. Am J Gastroenterol，2015，110（6）：836-844.
[5] Becker-Assmann J，Fard-Aghaie MH，Kantas A，et al. Diagnostic and prognostic significance of α-fetoprotein in hepatocellular carcinoma [J]. Chirurg，2020，91（9）：769- 777.
[6] Zhang YS，Chu JH，Cui SX，et al. Des-γ-carboxy prothrombin （DCP） as a potential autologous growth factor for the development of hepatocellular carcinoma [J]. Cell Physiol Biochem，2014，34（3）：903-915.
[7] Poté N，Cauchy F，Albuquerque M，et al. Performance of PIVKA-Ⅱ for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion [J]. J Hepatol，2015，62（4）：848-854.
[8] Peng F，Yuan H，Zhou YF，et al. Diagnostic Value of Combined Detection via Protein Induced by Vitamin K Absence or Antagonist Ⅱ，Alpha-Fetoprotein，and D-Dimer in Hepatitis B Virus-Related Hepatocellular Carcinoma [J]. Int J Gen Med，2022，15：5763-5773.
[9] Shen Q，Fan J，Yang XR，et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma：a large-scale，multicentre study [J]. Lancet Oncol，2012，13（8）：817-826.
[10] Kim SY，Lee HS，Bang SM，et al. Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma [J]. Cancers （Basel），2021，13（8）：1828.
[11] Han EK，Tahir SK，Cherian SP，et al. Modulation of paclitaxel resistance by annexin Ⅳ in human cancer cell lines [J]. Br J Cancer，2000，83（1）：83-88.
[12] Liu YY，Ge C，Tian H，et al. The transcription factor Ikaros inhibits cell proliferation by downregulating ANXA4 expression in hepatocellular carcinoma [J]. Am J Cancer Res，2017，7（6）：1285-1297.
[13] Saad ZM，Fouad Y，Ali LH，et al. Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma [J]. Asian Pac J Cancer Prev，2020， 21（9）：2661-2665.
[14] Zhou F，Shang W，Yu X，et al. Glypican-3：A promising biomarker for hepatocellular carcinoma diagnosis and treatment [J]. Med Res Rev，2018，38（2）：741-767.
[15] Bakheet AMH，Zhao C，Chen JN，et al. Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope techology [J]. Hepatol Int，2020，14（1）：96-104.
[16] Jia X，Liu J，Gao Y，et al. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma：a systematic review with meta-analysis [J]. Arch Med Res，2014，45（7）：580-588.
[17] Wu M，Liu Z，Li X，et al. Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma [J]. Onco Targets Ther，2020，13：827-840.
[18] Guo Y，Liu B，Huang T，et al. HOTAIR modulates hepatocellular carcinoma progression by activating FUT8/core-fucosylated Hsp90/MUC1/STAT3 feedback loop via JAK1/ STAT3 cascade [J]. Dig Liver Dis，2022，S1590-8658（22）00255-9.
[19] Wei W，Liu M，Ning S，et al. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma [J]. BMC Cancer，2020，20（1）：6.
[20] Fu Y，Xu X，Huang D，et al. Plasma Heat Shock Protein 90 alpha as a Biomarker for the Diagnosis of Liver Cancer：An Official，Large-scale，and Multicenter Clinical Trial [J]. EBio Medicine，2017，24：56-63.
[21] Huang Z，Zhou JK，Peng Y，et al. The role of long noncoding RNAs in hepatocellular carcinoma [J]. Mol Cancer，2020，19（1）：77.
[22] Kim SS，Baek GO，Ahn HR，et al. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma [J]. Mol Oncol，2020，14（10）：2646-2659.
[23] Kim SS，Baek GO，Son JA，et al. Early detection of hepatocellular carcinoma via liquid biopsy：panel of small extracellular vesicle-derived long noncoding RNAs identified as markers [J]. Mol Oncol，2021，15（10）：2715-2731.
[24] Zhang H，Ding R，Chen D. Value of miR-21 levels as potential biomarkers in the early diagnosis of hepatocellular carcinoma：a meta-analysis [J]. Biomarkers，2021，26（7）：586-597.
[25] Lin XJ，Chong Y，Guo ZW，et al. A serum microRNA classifier for early detection of hepatocellular carcinoma：a multicentre，retrospective，longitudinal biomarker identification study with a nested case-control study [J]. Lancet Oncol，2015，16（7）：804-815.
[26] Zang J，Lu D，Xu A. The interaction of circRNAs and RNA binding proteins：An important part of circRNA maintenance and function [J]. J Neurosci Res，2020，98（1）：87-97.
[27] Dong ZR，Ke AW，Li T，et al. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity [J]. Mol Cancer，2021，20（1）：75.
[28] Liang WC，Wong CW，Liang PP，et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway [J]. Genome Biol，2019，20（1）：84.
[29] Wei Y，Chen X，Liang C，et al. A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma [J]. Hepatology，2020，71（1）：130-147.
[30] Yu J，Ding WB，Wang MC，et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma：A large-scale，multicenter study [J]. Int J Cancer，2020，146（6）：1754-1763.
[31] Zhang L，Lu Q，Chang C. Epigenetics in Health and Disease [J]. Adv Exp Med Biol，2020，1253：3-55.
[32] Zhang YJ，Wu HC，Shen J，et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA [J]. Clin Cancer Res，2007，13（8）：2378-2384.
[33] Kisiel JB，Dukek BA，Kanipakam RVSR，et al. Hepatocellular Carcinoma Detection by Plasma Methylated DNA：Discovery，Phase Ⅰ Pilot，and Phase Ⅱ Clinical Validation [J]. Hepatology，2019，69（3）：1180-1192.
[34] Cai J，Chen L，Zhang Z，et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma [J]. Gut，2019，68（12）：2195-2205.